Selected References:
- Baard J, et al. 2020. The effect of beta-blockers on foetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study. Cardiovasc J Afr 31(3):136-141.
- Bateman BT, et al. 2016. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics 138(3):e20160731.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 20(2):138-45.
- Firoz T, et al. 2014. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG 121(10):1210-8.
- Ruys TP,et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol 177(1):124-8.
- Semczuk M. 1987. The effects of beta-adrenergic drugs on the human sperm motility in vitro. I. The effects of propranolol and isoprenaline. Andrologia. 19 Spec No:256-61.
- Tanaka K. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 80(10):2221-6.
- Wu Y. (2021). Risk of congenital malformations in offspring of women using β-blockers during early pregnancy: An updated meta-analysis of observational studies. Br J Clin Pharmacol 87(3):806-815.
- Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 175:124-8.
- Xie RH,et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG 121(9):1090-6.
